AbbVie Inc (NYSE: ABBV) announced on Friday the declaration by its board of directors of a quarterly cash dividend of USD1.07 per share.
This cash dividend is payable on 15 November 2019 to stockholders of record at the close of business on 15 October 2019.
The company added that since its inception in 2013, it has increased its dividend by 168%.
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions.
Mesa Labs closes acquisition of Gyros Protein Technologies for cash consideration of USD180m
UnitedHealth Group to pay dividend to holders of record as of 9 December 2019
KORU Medical Systems achieves higher USD0.02 per diluted share for Q3 2019
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia for upfront USD178m
Amgen announces Q3 2019 financial results
Allergan sets quarterly dividend payment date of 13 December 2019
NANOBIOTIX collects Q3 2019 revenues of EUR11,000
BioInvent signs production agreement with Cancer Research UK for HMBD-001
Veracyte Inc incurs lower net loss of USD0.7m for Q3 2019
Simulations Plus approves USD0.06 per share dividend for quarter
Omega to pay higher dividend of USD0.67 per common share for quarter
AstraZeneca divests global commercial rights for Losec to Cheplapharm for USD243m
Bactiguard announces global license agreement with Zimmer Biomet for orthopaedic trauma implants